Pulmonology

AdaptHealth To Participate In BofA Securities Home Care Conference

Retrieved on: 
Wednesday, November 30, 2022

AdaptHealth Corp. (NASDAQ: AHCO) (AdaptHealth or the Company), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that Steve Griggs, CEO, Josh Parnes, President, and Jason Clemens, CFO, will participate in a fireside chat at the BofA Securities Home Care Conference on Monday, December 5, at 2:00 pm ET.

Key Points: 
  • AdaptHealth Corp. (NASDAQ: AHCO) (AdaptHealth or the Company), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that Steve Griggs, CEO, Josh Parnes, President, and Jason Clemens, CFO, will participate in a fireside chat at the BofA Securities Home Care Conference on Monday, December 5, at 2:00 pm ET.
  • A live webcast and replay will be accessible through the Investors section of AdaptHealths website ( www.adapthealth.com ).
  • Please visit AdaptHealths website approximately 5-10 minutes prior to the presentation to register and download any necessary audio software.
  • AdaptHealth is a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services.

Surgical Sealants, Adhesives and Hemostats Global Market Forecast to 2029: Acquisitions to Open An Array of Opportunities for the Market to Flourish - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 30, 2022

The "Surgical Sealants, Adhesives and Hemostats Global Market - Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Surgical Sealants, Adhesives and Hemostats Global Market - Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
  • The SAH global market is mainly segmented based on products, applications, end-users, and based on geography.
  • Among these, the hemostat accounted for the largest revenue in 2022 and is expected to grow at mid-single digit CAGR from 2022 to 2029.
  • The synthetic sealant accounted for the largest revenue in 2022 and is expected to grow at mid-single digit CAGR from 2022 to 2029.

Hoag is the First Hospital in Orange County to Perform Breakthrough Treatment Option for Patients with Severe COPD/Emphysema

Retrieved on: 
Tuesday, November 29, 2022

NEWPORT BEACH, Calif., Nov. 29, 2022 /PRNewswire/ -- Hoag is the first hospital in Orange County to perform a new lung valve treatment on a patient with severe COPD (chronic pulmonary obstructive disease) and emphysema. The procedure has the potential to benefit a number of patients in Orange County who suffer from major quality of life issues related to shortness of breath.

Key Points: 
  • NEWPORT BEACH, Calif., Nov. 29, 2022 /PRNewswire/ -- Hoag is the first hospital in Orange County to perform a new lung valve treatment on a patient with severe COPD (chronic pulmonary obstructive disease) and emphysema.
  • The procedure has the potential to benefit a number of patients in Orange County who suffer from major quality of life issues related to shortness of breath.
  • "We are thrilled to bring this minimally invasive option to patients in Orange County," said Javier Longoria, M.D., the only fellowship-trained interventional pulmonologist in Orange County, who performed the first procedure earlier this month.
  • "Finally having a breakthrough treatment option to help patients with this disease get back to their best self is very exciting," said Dr. Longoria.

APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival

Retrieved on: 
Sunday, November 27, 2022

Geneva, Switzerland, November 21, 2022 RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTD) (Relief), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, rare and ultra-rare disease areas on a global basis, today announced that its wholly owned subsidiary APR Applied Pharma Research SA (APR) has been nominated as a finalist in the 2022 Rare Disease International Film Festival UnoSguardoRaro .

Key Points: 
  • Geneva, Switzerland, November 21, 2022 RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTD) (Relief), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, rare and ultra-rare disease areas on a global basis, today announced that its wholly owned subsidiary APR Applied Pharma Research SA (APR) has been nominated as a finalist in the 2022 Rare Disease International Film Festival UnoSguardoRaro .
  • APR supports and contributes to the first and only European film festival showcasing films from around the world that address the challenges of life with a rare disease.
  • As part of its participation in the festival, APR attended events in Berlin (Il Kino), Rome (la Casa del Cinema) and Milan (Niguarda hospital).
  • The festival earned the support of many rare disease associations such as:
    PKU GOLIKE is a phenylalanine-free food intended for the dietary management of phenylketonuria (PKU).

Beyond Air® To Participate in Piper’s 34th Annual Healthcare Conference

Retrieved on: 
Thursday, November 17, 2022

Piper 34th Annual Healthcare Conference November 29-December 1, 2022

Key Points: 
  • Piper 34th Annual Healthcare Conference November 29-December 1, 2022
    If you are interested in requesting a 1x1 meeting at the respective conference, please contact your bank/conference representative.
  • For more details, please see the Events section of Beyond Airs corporate website.
  • The Company has received FDA approval for its first system, LungFit PH for persistent pulmonary hypertension of the newborn.
  • Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made.

RS BioTherapeutics Selects Recipharm as Product Characterization Partner

Retrieved on: 
Monday, November 14, 2022

Commenting on the partnership, Justin Molignoni, Chief Strategy Officer of RS BioTherapeutics said, We are very pleased to partner with Recipharm for product characterization testing to support the development of RSBT-001 as a treatment for COPD.

Key Points: 
  • Commenting on the partnership, Justin Molignoni, Chief Strategy Officer of RS BioTherapeutics said, We are very pleased to partner with Recipharm for product characterization testing to support the development of RSBT-001 as a treatment for COPD.
  • Chris Hirst, Head of Recipharms Advanced Delivery Systems Business Unit said, Recipharm is delighted to be working with RS BioTherapeutics, providing product characterization testing to support the development of RSBT-001.
  • In July, RS BioTherapeutics announced positive results from its proof-of-concept study with its development partner Synthonics and Marshall University, for RSBT-001.
  • Founded by experts in pulmonary diseases and the endocannabinoid system, RS BioTherapeutics is a wholly owned subsidiary of Real Science Holdco LLC.

Savara Announces New Employment Inducement Grant

Retrieved on: 
Tuesday, November 22, 2022

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of an employee inducement award.

Key Points: 
  • Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of an employee inducement award.
  • The inducement award consists of options to purchase 375,000 shares of the Companys common stock and restricted stock units (RSUs) covering 150,000 shares of the Companys common stock.
  • This equity award was granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material to the employees acceptance of employment with the Company.
  • The RSUs vest in full on the two-year anniversary of the employees first day of employment, subject to the employees continued employment on such vesting date.

Stevens Nation Responds to FDA's Refusal to File Letter, NurOwn Recipients Call for Advisory Committee Meeting

Retrieved on: 
Tuesday, November 22, 2022

WASHINGTON, Nov. 21, 2022 /PRNewswire/ -- Brainstorm Cell Therapeutics is seeking FDA approval of its mesenchymal stem cell therapy called NurOwn for the treatment of ALS. In response to the FDA's Refusal to File letter, and as people who participated in the NurOwn trials and its Expanded Access program ("EAP"), we support Brainstorm's efforts to seek an Advisory Committee ("AdCom") meeting.

Key Points: 
  • In response to the FDA's Refusal to File letter, and as people who participated in the NurOwn trials and its Expanded Access program ("EAP"), we support Brainstorm's efforts to seek an Advisory Committee ("AdCom") meeting.
  • We must insist that the FDA allow testimony about the "clinically meaningful" changes that occurred when we received NurOwn.
  • However, the Phase III trial did meet a pre-specified secondary endpoint in a subgroup of patients with less advanced ALS.
  • The best people to attest to how NurOwn made them "feel and function" are the people who received NurOwn.

APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival

Retrieved on: 
Monday, November 21, 2022

GENEVA, Nov. 21, 2022 /PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX: RLF) (OTCQB: RLFTF) (RLFTD) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, rare and ultra-rare disease areas on a global basis, today announced that its wholly owned subsidiary APR Applied Pharma Research SA ("APR") has been nominated as a finalist in the 2022 Rare Disease International Film Festival UnoSguardoRaro.

Key Points: 
  • GENEVA, Nov. 21, 2022 /PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX: RLF) (OTCQB: RLFTF) (RLFTD) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, rare and ultra-rare disease areas on a global basis, today announced that its wholly owned subsidiary APR Applied Pharma Research SA ("APR") has been nominated as a finalist in the 2022 Rare Disease International Film Festival UnoSguardoRaro.
  • APR supports and contributes to the first and only European film festival showcasing films from around the world that address the challenges of life with a rare disease.
  • During the awards ceremony, the jury awarded APR's movie 2 prizes: Special Mention for Best Campaign and Best Direction.
  • The festival earned the support of many rare disease associations such as:
    PKU GOLIKE is a phenylalanine-free food intended for the dietary management of phenylketonuria ("PKU").

Body Vision Medical Announces Market Entry and First Customer in India

Retrieved on: 
Thursday, November 17, 2022

CAMPBELL, Calif., Nov. 17, 2022 /PRNewswire/ -- Body Vision Medical, a leader in AI-driven, intraoperative imaging, announced today they have signed an exclusive distribution agreement with SCHILLER Healthcare India Pvt. Ltd., and that Yashoda Hospitals in Hyderabad plans to acquire a LungVision™ System, which, upon installation, will be the first in India.

Key Points: 
  • Body Vision Medical's LungVision System uses artificial intelligence (AI) to transform X-ray images from any C-arm into real-time, intraoperative CT scans.
  • Body Vision Medical's strategic partnership with SCHILLER Healthcare India will accelerate Body Vision's penetration of the Indian market.
  • "We are pleased to collaborate with Body Vision Medical to distribute and support their products in India," said Vikram Sanghvi, CEO and MD of SCHILLER Healthcare India Pvt.
  • https://doi.org/10.1136/bmj.l408
    Body Vision Medical specializes in AI-driven, intraoperative imaging with the aim of saving lives through the democratization of innovative medical technology.